MEMPHASYS LIMITED. — Investor Presentation 2012

Jun 5, 2012

Investor Presentation

June 2012

DISCLAIMER

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

Entering the Asian Plasma Markets PrIME - A Game Changer

Human Plasma - Liquid Gold Limited Supply - 50% Discarded

Human Plasma contains multiple products just like a barrel of oil

• •Greater than 50% of all the Plasma collected in Asia is Discarded (CUP)*
• •Plasma currently accounts for over 80% of the total manufacturing cost
• •Processing this Discarded Plasma is Game Changing

Asian Market Situation

Worldwide Therapeutic Plasma Market is \$16b

….

Asia accounts for 21% of world market but represents 60% of the world population

Entering Asian Emerging Markets

Market Opportunity:

•Profitably make a SAFE & AFFORDABLE Product.

Can be Achieved by:

•Processing Discarded Plasma (CUP)

Requires:

• •A Disposable manufacturing process – PrIME
• •Higher production yield than current processes

The PrIME Market Entry Strategy

Therapeutic Products

Market Entry Model and Order book

Order Book– Yearly

India:

Singapore: 10,000 Litres 50,000 Litres

Revenue:

S\$32M (A\$25M)

Plasma is drawn from India, Processed in Singapore and sold back to India as an Active Ingredient

Market Entry Risks

• • Technology – This is NOT a technology play. Very Low technology risk.
• • Regulatory Minimal, only require cGMP approval from Singapore Health Sciences Authority. Singapore facility was previously cGMP approved and FDA audited.
• • Execution Low, risk mitigated through employment of HSA personnel and contracts for all key commercial elements.
• • IP– Very Low, Patent protection and partnering with local organisations reduces commercialisation risk.

PrIME Singapore Budget

\$ i S B d t g e n u C l d a e n a r e a r s y	2 0 1 2 \$ S M	2 0 1 3 \$ S M	2 0 1 4 \$ S M	2 0 1 5 \$ S M
S l a e s	\$ * 0 5	\$ * 3 0	\$ 3 2 7	\$ 4 9 9
G P f i t r o s s r o	\$ ( ) 0 4	\$ 0 4	\$ 2 4 5	\$ 3 8 7
O P E X	\$ ( ) 3 0	\$ ( ) 4 4	\$ ( ) 4 2	\$ ( ) 4 8
E B I T D A	\$ ( ) 3 3	\$ ( ) 2 9	\$ 1 9 2	\$ 2 9 2
N P A T	\$ ( ) 3 4	\$ ( ) 4	\$ 1 8 1	\$ 2 8 1

NPV on the Singapore Project with a 15% Discount is S\$69m IRR on the Singapore Project is 55%

* Sales from distribution of existing therapeutic products

Singapore Plant: Reverse Osmosis Water Tank

Singapore Plant: 200L Bioreactor, Harvest and Permeate Tank

Singapore Plant: WFI Plant

Conclusion

• •Disruptive Market Entry Strategy by processing CUP.
• •Time to Market – First Sales in 18 months.
• •Singapore Government Funding & Support.
• •US\$20m HOA with ABS to fund Singapore project.
• •3 Year payback with an IRR of 55%.
• • Ongoing Revenue Stream to NuSep via Membrane Sales.
• •Significant growth via worldwide Rollout of PrIME.